is essential for deciphering genetic mechanisms of autoimmunity 4,5 . Here, we characterized the dynamics of genetic regulatory effects at eight time points during memory CD4 + T cell activation with high-depth RNA-seq in healthy individuals. We discovered widespread, dynamic allele-specific expression across the genome, where the balance of alleles changes over time. These genes were enriched fourfold within autoimmune loci. We found pervasive dynamic regulatory effects within six HLA genes. HLA-DQB1 alleles had one of three distinct transcriptional regulatory programs. Using CRISPR-Cas9 genomic editing we demonstrated that a promoter variant is causal for T cell-specific control of HLA-DQB1 expression.
We stimulated memory CD4 + T cells from 24 genotyped individuals of European ancestry ( Supplementary Fig. 1 ) with anti-CD3/ CD28 beads. We performed RNA-seq at 0, 2, 4, 8, 12, 24, 48 and 72 h after stimulation ( Fig. 1a ). Gene expression principal component analysis (PCA) showed that the 200 samples were separated by time ( Fig. 1b and Supplementary Fig. 2 ), and gene clustering identified activation and repression clusters ( Supplementary Fig. 3 ). Using a logistic regression framework, we identified dynamic ASE (dynASE) events at heterozygous SNPs. At these dynASE sites, the imbalance of the two expressed alleles is time dependent. First, for each heterozygous site in an individual, we merged counts from all time points and identified significant ASE. We queried a total of 207,519 sites, representing 38,890 unique SNPs in 8,322 genes and some in transcribed intergenic regions (3%) ( Supplementary  Fig. 4 ). We observed a total of 15,268 ASE events (intercept P < 2.4 × 10 −7 = 0.05/207,519 tests) within 2,147 genes. Next, we checked ASE sites for dynASE events by fitting a second-order polynomial model, thus modeling linear and nonlinear ASE effects with respect to time. To account for overdispersion of allelic counts [14] [15] [16] , we incorporated sample-to-sample variability with a random intercepts effect. We observed 561 significant dynASE events across the genome (P < 3.2 × 10 −3 , <5% false discovery rate (FDR)), representing 356 SNPs in 186 genes and seven intergenic sites ( Fig. 1c and Supplementary Table 1 ). These dynASE events show high reproducibility and expand on the known cis-regulatory genetic effects in T cells 6, 8, 9 (Supplementary Figs. 5 and 6, Extended Data Figs. 1-4 and Supplementary Note). For example, we observed dynASE in F11R and CXCR5 (Fig. 1d) , where the reference and alternative alleles were dynamically regulated in time.
It is possible that differences in regulatory complex activity over time both influences expression of a gene and results in differential binding of alleles in regulatory elements. If this is so, we would expect to see an association between changes in level of expression of the gene and changes in allelic imbalance over time (that is, the absolute difference between the observed allelic fraction and 0.5). As expected, when we calculated the Spearman rank correlation at each dynASE site between its allelic imbalance and expression over time, we observed a bimodal distribution of positive and negative associations ( Fig. 2a ). For example, SNP rs6021 [A>G] in gene F5 has a negative correlation between allelic imbalance and gene expression, with allelic imbalance starting high at 0 h (red circle in Fig. 2b ), going down as expression increases and going back up as expression decreases. In contrast, the SNP rs41306241[A>G] in the gene CTSL1 has a positive correlation between allelic imbalance and gene expression ( Fig. 2b) . Hence, dynamic ASE suggests complex differential usage of cis-regulatory elements during T cell activation affected by genetic variation.
We found that 31 of our dynASE genes were within autoimmune disease loci outside the major histocompatibility complex (MHC), including UBASH3A and IL10 (Fig. 2c,d ). DynASE genes are significantly enriched for risk loci for ankylosing spondylitis (odds ratio (OR) = 5.7, P = 0.008), celiac disease (OR = 5.4, P = 0.004), vitiligo (OR = 5, P = 0.004), type 1 diabetes (OR = 4.5, P = 0.002), inflammatory bowel disease (OR = 3.7, P = 0.001), rheumatoid arthritis (OR = 3.6, P = 0.005) and multiple sclerosis (OR = 3.1, P = 0.003), but not for 
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nonimmune-mediated diseases ( Fig. 2e , Methods, Supplementary Note and Supplementary Fig. 7 ). We compared these enrichments to genes with ASE at 0 h only, and with published expression quantitative trait loci (eQTL) in resting CD4 + naïve T cells 9 . We observed that our dynASE genes, spanning up to eight different cellular states, had the highest enrichment for autoimmune loci (Fig. 2e ). . N = 24 for gene expression, 1 for ASE. e, Fold enrichment of dynASE genes (blue) in risk loci for autoimmune diseases and three nonimmune-mediated diseases, using 1,000 null sets of loci matched by number of loci per disease and number of genes per locus. Similarly for genes with significant ASE at 0 h (green) and naïve T cell eQTL genes (pink). Filled circles mark permutation P < 0.01, empty circles mark permutation P > 0.01.
We observed 182 dynASE events within the MHC locus ( Fig. 1c ), with 15 events in HLA-DQB1 (examples in Supplementary Fig. 8 and Supplementary Table 1 ), which harbors most of the genetic risk for type 1 diabetes and celiac disease 17, 18 . HLA-DQB1 is part of HLA class II, which encodes antigen-presenting proteins that are typically expressed by professional antigen-presenting cells. In human T cells these genes are recognized as activation markers, and are expressed by T cell subsets that are expanded in patients with autoimmune disorders [19] [20] [21] [22] [23] . The literature suggests that T cells may present antigens to alter immune responses [24] [25] [26] . However, the function of HLA class II in T cells remains controversial.
To define the relationship between HLA classical alleles (a combination of multiple coding variants) and regulatory variation, we performed high-resolution typing of HLA-DQB1, HLA-DRB1, HLA-DQA1, HLA-A, HLA-B and HLA-C, for all 24 individuals. To robustly identify dynASE in this highly polymorphic region, we built an HLA-personalized genome for each individual (Extended Data Fig. 5 ) and quantified the number of uniquely mapped reads to each HLA allele per individual. Among the 48 HLA-DQB1 ~780base pair (bp) sequences, there were 14 HLA-DQB1 four-digit classical alleles. Our HLA-personalized genome strategy quantified expression of HLA-DQB1 alleles by taking advantage of >20 SNPs in four exons ( Fig. 3a,b ; replication in Extended Data Fig. 6 ). With this strategy, we determined that most (15/24) individuals have significant dynASE for HLA-DQB1 (P < 0.002 = 0.05/24 tests; examples in Fig. 3c ).
Allelic expression profiles of HLA-DQB1 four-digit classical alleles clustered together more than would be expected by chance (permutation P < 0.001, Supplementary Fig. 9 ), suggesting that cisregulatory effects segregate with HLA-DQB1 classical coding alleles. We observed three transcriptional cis-regulatory programs: Late-Spike, Constant-Low and Fluctuating ( Fig. 3d and Extended Data Fig. 7 ). This identifies three distinct transcriptional profiles in HLA-DQB1 expression over time, thus describing particularly complex and variable regulation in this gene.
We wanted to confirm that the drastic upregulation of messenger RNA in the Late-Spike cis-regulatory program affected cell-surface protein expression levels. We recruited five independent homozygous individuals with HLA-DQB1 classical alleles with the Late-Spike cis-regulatory program and five homozygous individuals for HLA-DQB1 classical alleles with Constant-Low or Fluctuating cisregulatory programs ( Supplementary Fig. 10 ). After 7 d of activating memory CD4 + T cells, we observed that the fold change increase in HLA-DQ cell-surface expression was significantly higher in Late-Spike homozygotes (P = 0.03, Wilcoxon test; Fig. 3e and Supplementary Fig. 11 ).
We then sought to identify the genetic variant driving the Late-Spike cis-regulatory program using genetic and epigenetic fine-mapping tools. We called SNP genotypes and four-digit classical HLA alleles in 2,198 fully sequenced whole genomes from Estonia 27 . We identified SNPs in tight linkage disequilibrium (LD) with the Late-Spike HLA-DQB1 classical alleles, which together represent what we henceforth call the Late-Spike haplotype. While most of the SNPs in highest LD with this haplotype (r 2 ≥ 0.96) were within the HLA-DQB1 gene (89%), only six were intergenic ( Fig. 4a and Extended Data Fig. 8a ). The same six variants emerged in an eQTL analysis in our cohort of 24 individuals, and in an independent analysis in another European descent cohort from the United States 28 (N = 1,603) (Supplementary Note and Extended Data Fig. 8b-d ). We applied ATAC-seq in memory CD4 + T cells after 72 h of stimulation to identify open chromatin regions. Among these six SNPs, we observed that the rs71542466[C>G] SNP overlapped the highest ATAC-seq peak. In publicly available data, we also observed that this SNP overlapped other regulatory element marks and peaks for HLA class II regulators 29-31 ( Fig. 4a and Supplementary Fig. 12 ).
We hypothesized that one of the six intergenic SNPs in phase with the Late-Spike haplotype were causal and influenced gene regulation. If so, (1) the causal SNP should be in regions that have regulatory activity and (2) editing the allele of the causal SNP itself should influence gene expression. To this end, we used CRISPR-Cas9 editing in HH cells, an HLA class II-expressing T cell line, to test the regions around all six candidate SNPs for regulatory activity ( Supplementary Fig. 13 ). After cutting near the six SNPs, only editing near rs71542466, located 39 bp upstream of the transcription start site, caused significant decrease in HLA-DQ expression ( Fig. 4b and Extended Data Fig. 9 ). Next, we applied targeted homology-directed repair (HDR) with CRISRPR-Cas9 to rs71542466, to convert the reference C allele to the alternative G allele. We predicted that the HH T cell line clones that are homozygous for the rs71542466 reference allele should have lower HLA-DQB1 expression than base-edited clones homozygous for the alternative allele. We identified seven clones homozygous for the alternative G allele, seven clones homozygous for the reference C allele and one clone with a 104-bp deletion (Extended Data Fig. 10 ). As predicted, HLA-DQB1 was higher in alternative allele clones by real-time PCR (P = 0.003, Fig. 4c ). After extended culture, surviving alternative allele clones also had higher expression of HLA-DQ protein by flow cytometry (P = 0.03, Fig. 4c ). These results confirmed that the rs71542466 promoter SNP changes HLA-DQB1 expression and that it accounts for the Late-Spike cis-regulatory program. We cannot rule out, however, that additional variants inside HLA-DQB1 (such as those within the untranslated region or intragenic enhancers) may also contribute.
After identifying rs71542466 as an HLA-DQB1 condition-specific regulatory variant, we considered whether its effect is T cell specific. Notably, the rs71542466 SNP was not in LD with reported eQTL SNPs for HLA-DQB1 in B cell-derived lymphoblastoid cell lines, monocytes and resting and infected macrophages (Supplementary Table 2 , r 2 ≤ 0.27)) 8, 9, [32] [33] [34] . Luciferase assays, electrophoretic mobility shift assays (EMSA) in cell lines and flow cytometry data in primary B cells further confirmed that the activation-dependent regulatory effect is T cell specific ( Fig. 4d ,e, Supplementary Figs. 15 and 16 and Supplementary Note; see also the source data for Fig. 4 and Supplementary Fig. 15 ).
We observed dynASE in five HLA genes besides HLA-DQB1. Within HLA class II genes, HLA-DRB1 had significant dynASE in 9 individuals (P < 2.1 × 10 −3 = 0.05/24 tests), and HLA-DQA1 in 6 individuals (P < 2.2 × 10 −3 = 0.05/23 tests). Within HLA class I genes, HLA-B and HLA-C had significant dynASE in 12 individuals (P < 2.3 × 10 −3 = 0.05/22 tests and P < 2.4 × 10 −3 = 0.05/21 tests) and HLA-A in 6 individuals (P < 2.3 × 10 −3 = 0.05/22). However, for these five genes, the magnitude of change in allelic fraction across time was more modest than for HLA-DQB1 ( Supplementary  Fig. 17 ). We noticed that individuals with a Late-Spike HLA-DQB1 allele often have a similar pattern of expression over time for the HLA-DRB1 allele on the same chromosome (on the basis of phasing), with upregulation of expression at 48 and 72 h (examples in Supplementary Fig. 18a ). This suggests that ciscoregulation between these two genes could be mediated through promoter-promoter interactions between HLA-DQB1 and HLA-DRB1, which is consistent with promoter capture HiC data ( Supplementary Fig. 18b ) 35, 36 .
Here, we observed that allelic imbalance in expression is highly dependent on time after stimulation of memory CD4 + T cells. In most cases, one of the two alleles over time gradually increased expression over the other allele (for example, UBASH3A, CXCR5). We suspect these cases are a consequence of a regulatory complex interacting with a single genetic variant altering gene expression; where the status of the regulatory complex may vary depending on the environmental context over time. However, in many instances, we observed that the dominant expressed allele switched Letters Nature GeNetics as stimulation progressed (for example, HLA-DQB1, F11R), raising the possibility of multiple regulatory variants or complexes. For example, we identified distinct driving variants for HLA-DQB1 at 0 and 72 h after stimulation (LD r 2 = 0.01, Supplementary  Table 2 ). Overall, this widespread dynamic allelic imbalance across the genome illustrates the continuously changing regulatory landscape of genes during T cell activation. We predict that future studies with larger sample sizes for ascertaining additional cellular states will reveal that dynamic ASE is even more widespread than has been conservatively identified in this study.
We found that dynASE genes were highly enriched in autoimmune disease loci, suggesting that autoimmune risk alleles may affect the expression of their target gene under very specific conditions. Indeed, an autoimmune risk variant in an IL2RA enhancer has already been shown to act in a time-dependent manner, influencing polarization of T cells into an inflammatory subtype (T H 17) instead of the regulatory population (T reg ) 4 . These results may explain why investigators have found limited shared genetic effects between autoimmune susceptibility variants and eQTL variants at resting state 3, 12, 37 , despite the presence of autoimmune susceptibility variants in regulatory elements [1] [2] [3] 38 .
Intriguingly, we identified dramatic T cell and condition-dependent cis-regulatory variation within a major autoimmune disease gene: HLA-DQB1. This raises the question of whether, and to what extent, genetic regulatory variation controlling HLA gene expression could affect disease susceptibility or disease penetrance, as has been highlighted for other loci and traits 39 . For most autoimmune diseases, the MHC region is the major contributing locus to disease risk. In this study, three of the four Late-Spike HLA-DQB1 classical alleles are protective for type 1 diabetes (OR, 0.045-0.732), while the other two regulatory programs represent a mixture of risk and protective alleles 17 . While amino acid changes causing differential antigen display may be the primary autoimmune mechanism at the HLA locus 17, 40 , our data underscore the possibility that expression levels of HLA class II may also play a crucial and unappreciated role 41, 42 . Over the past several decades there has been literature suggesting variation in expression among different HLA alleles 34,43-45but to date the idea that this regulation changes with cell state has not been established.
Broadly, class II expression has been well characterized as a marker for both late activation in CD4 + T cells and suppressive capacity in T-regulatory cells [46] [47] [48] . However, the exact mechanisms and functional implications remain to be defined. Our work shows that not only do CD4 + T cells express high levels of HLA class II, but also that this expression is regulated in a cell-type-specific manner and varies between individuals. This suggests that during immune 
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Methods Study design. The goal of this study was to characterize cell state-dependent regulatory effects in memory CD4 + T cells, to obtain new insights into autoimmune disease mechanisms. In initial experiments, we observed the most dramatic dynamic allele-specific expression effects in HLA-DQB1. To investigate this phenomenon in an optimal way, we recruited individuals heterozygous for common HLA-DQB1 classical alleles (characterized by a combination of coding single nucleotide alleles), with highly divergent alleles (at least a 20 mismatch difference between the two alleles). We used the anonymized genome-wide genotypes available from the individuals at the Genotype and Phenotype (GaP) Registry at The Feinstein Institute for Medical Research to impute HLA classical alleles with SNP2HLA 49 and select individuals. The GaP Registry provided anonymized cryopreserved peripheral blood mononuclear cells (PBMCs) from 24 donors with no autoimmune disease, 20-50 years old and of European ancestry. Donors provided fresh, anonymized human PBMCs; blood was collected from subjects under an IRB-approved protocol (IRB no. 09-081) and processed to isolate PBMCs. The GaP is a subprotocol of the Tissue Donation Program at Northwell Health and a national resource for genotype-phenotype studies 50 . HLA classical alleles were subsequently confirmed experimentally with HLA typing (see below). Similarly, for the protein-level validation experiments, we recruited individuals who were homozygous for HLA-DQB1 classical alleles pertaining to the Late-Spike regulatory program (N = 5) or other programs (N = 5) through the GaP Registry. These individuals were also 20-50 years old, with no reported autoimmune disease and of European ancestry.
Additional details can be found in the Life Sciences Reporting Summary associated with this article.
Memory CD4 + T cell stimulation time course.
PBMCs were thawed and resuspended in prewarmed complete RPMI (cRPMI) (RPMI 1640, supplemented with 10% heat-inactivated FBS and 1% nonessential amino acids, sodium pyruvate, HEPES, l-glutamine, penicillin and streptomycin and 0.1% β-mercaptoethanol). Memory CD4 + T cells were isolated by magnetic selection (Miltenyi, Memory CD4 + T cell isolation kit human). One million cells per well were plated in sterile 48-well plates (Corning) and rested at 37 °C overnight. Twelve hours after the beginning of the rest marked the first time point (0 h). At this time, cells were spun down and resuspended in 350 µl of RLT lysis buffer (Qiagen) containing β-mercaptoethanol and stored at −80 °C. To the remaining wells, 500 µl cRPMI with human T-activator CD3/CD28 Dynabeads (Gibco) was added to each well at a ratio of 2 cells:1 bead. Cells were collected at 2, 4, 8, 12, 24, 48 and 72 h after stimulation. Once all cell pellets were collected, resuspended in RLT and frozen, the RNA was isolated using an RNeasy mini kit (Qiagen) and stored at −80 °C until submitted for sequencing at the Broad Institute.
Library construction and RNA sequencing. RNA-seq library preparations were performed with an Illumina TruSeq stranded mRNA sample preparation kit, and 101-bp paired-end reads were sequenced at a mean depth of 41 million fragments (read pairs). Additional details can be found in the Supplementary Note.
Gene expression analyses.
We mapped reads to the hg19 reference genome with subread v.1.5.1 (ref. 51 ) (with parameters: -u -Q -D 100000 -t 0 -T 4) and quantified expression levels using featureCounts (with parameters: -T 4 -Q 20 -C -s 2 -p -P -D 100000) and GENCODE 52 v.19 annotation. For PCA we took 1,070 genes with standard deviation >1 and mean expression >3 log 2 (tpm + 1) (tpm, transcripts per million), we scaled gene to mean zero and variance one and performed PCA with the R function 53 prcomp. For gene clustering, we used k-means. Enrichment of MSigDB hallmarks v.6.2 (refs. 54, 55 ) was performed with the enricher function of the R package clusterProfiler 56 .
In all box plots in the manuscript, boxes show the first to third quartile with median, whiskers encompass 1.5× the interquartile range and data beyond that threshold are indicated as outliers.
Variant genotyping, imputation and filtering. Individuals were genotyped genome wide using the Global Screening Array assaying 647,000 SNPs. For preimputation quality control, we used plink v.1.90b3w 57 to filter out variants with missing call frequencies greater than 0.05, Hardy-Weinberg equilibrium threshold P < 1 × 10 −5 , minor allele frequency (MAF) 0.03, keeping a total of 339,333 variants. We imputed variants into the 1000 Genomes reference panel 58 using SHAPEIT v.2.r837 (ref. 59 ) and IMPUTE2 v.2.3.2 (ref. 60 ). We filtered out variants with an 'info score' <0.9, multiallelic, Hardy-Weinberg equilibrium threshold P < 1 × 10 −5 , nonpolymorphic within our 24 individuals, and with MAF < 1% in Europeans of the 1000 Genomes reference panel and indels. This yielded a total of 5,144,453 SNPs. When selecting heterozygous SNPs per individual, we further required a genotype probability of >0.9; a total of ~1.5 million heterozygous SNPs per individual remained.
Dynamic allele-specific expression analysis. We used subread v.1.5.1 to align reads to the hg19 reference genome and filtered out reads with mapping quality <10. We used WASP 15 to filter out reads that had mapping bias at heterozygous sites and to remove duplicates. For quantifying allele counts at heterozygous sites, we used GATK 61 v.3.8 ASEReadCounter requiring a minimum read mapping quality of 10 and a minimum base quality of 10 for the site in question (with parameters --minMappingQuality 10, --minBaseQuality 10, -U ALLOW_N_ CIGAR_READS), and we followed recommended best practices 62 . For initial quality control ( Supplementary Fig. 4 ), for each sample we took all heterozygous sites with at least 10 reads (6,496-44,864 sites per sample). The mean coverage across sites per sample ranged from 50 to 127. All samples had >95% of both alleles observed at included heterozygous sites. The mean reference fraction was close to 0.5 for all samples (mean 0.5098, range from 0.5045 to 0.5159). For a given heterozygous site, the reference fraction refers to the number of reads with the reference allele divided by the total number of reads overlapping the site. Allelic imbalance is the distance to 0.5 reference fraction (that is, absolute value of the reference fraction minus 0.5).
To identify sites with dynamic ASE, we used a nested approach using a logistic regression framework on a per individual, per heterozygous site basis, with the lme4(ref. 63 ) R package. Each read was encoded according to the following: 1 if it contains a reference allele or 0 if it contains the alternative allele. For each time course per individual, we included sites with at least 20 reads in at least four time points and required that both reference and alternative alleles were seen in all included samples. First, we identified sites with evidence of ASE by merging data from all time points and testing whether the intercept was significantly different from zero (assuming a standard normal distribution and using a two-sided z-test) and used a Bonferroni threshold to determine significance (0.05 divided by the number of tests). Then, we tested which of these sites had ASE that changes with time by fitting a second-order polynomial model, which allowed modeling of nonlinear ASE effects with respect to time. Time was coded as time points 1 to 8 (or maximum number of time points) and scaling to mean zero variance 1. We controlled for overdispersion of allelic counts due to technical or biological sample-to-sample variability 16 by incorporating a random intercept effect, coding the sample identity as a factor. We tested for the effects of time by performing a likelihood ratio test between the two nested models using the R anova function (two-sided). The null model, H 0 , and alternative model, H 1 , for a given SNP, i, in a given individual, j, are detailed in the following equations:
where p is the probability of observing the reference allele, α is the intercept, μ is the random intercept effect across samples, t is time and β is the effect of time on the log-odds of observing the reference allele. We calculated the FDR per test using the qvalue R package 64 , and called all events with q < 0.05 (<5% FDR) as significant, unless otherwise stated. Using a quadratic function identified twice as many events as a linear function, while capturing most of the linear events (87%).
HLA typing.
Purified DNA from the 24 individuals was sent to NHS Blood and Transplant, UK, where HLA typing was performed. Next-generation sequencing was done for HLA-DQB1, HLA-A, HLA-B, HLA-C and for HLA-DRB1. PCRsequence-specific oligonucleotide probe amplification was performed for HLA-DQA1 in all individuals, and for HLA-DRB1 in six individuals for whom limited DNA was available. These typing methods yielded classical allele calls for the six genes at four-to eight-digit resolution.
Allele-specific expression in HLA genes. To prepare an HLA-personalized genome for each individual we first took the HLA six-digit classical allele calls for each of the six HLA genes (12 alleles total per individual) and downloaded the corresponding complementary DNA sequence from the IPD-IMGT/HLA database 65 . Next, we added the 12 HLA allele cDNA sequences to the hg19 reference genome, each encoded as a separate chromosome. We masked the exonic regions of the six HLA genes on chromosome 6 in the original hg19 reference (by replacing the A, T, C and G bases with Ns), to remove redundancy with the added cDNA sequences (so that reads will map to only the cDNA sequences and not the original reference genome sequences). For each individual, we aligned, per sample, the reads to the HLA-personalized genome with subreads requiring uniquely mapped reads. We removed PCR duplicates with Picard Tools v.1.119. We counted the number of uniquely mapped reads to each HLA allele with featureCounts, requiring a minimum mapping quality of 40 and using a personalized gtf annotation file per individual. In this way, we obtained quantifications of each of the six HLA alleles, as though each was a separate gene.
To identify dynASE for each HLA gene, we used the same statistical approach mentioned above. Instead of using allele counts for a single SNP, we used counts for the whole cDNA per HLA allele (usually encompassing 3-4 exons, 552-1,119 bp). To compare HLA allelic expression levels between samples, we normalized the HLA allele counts by library size and cDNA size (FPKM, fragments per kilobase million). For the two individuals for whom we had full time-course replicates, we used the mean of the FPKM values.
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For testing whether allelic profiles of HLA-DQB1 four-digit classical allele groups are more similar to each other than would be expected by chance, we calculated the sum of squares within four-digit allele groups, and the total sum of squares (observed values). Then, we permutated the four-digit allele groups 10,000 times, and repeated the sum of squares calculations ( Supplementary Fig. 9 ). For this analysis, we excluded four allelic profiles with four-digit alleles that were present only once in our 48 allelic profiles (DQB1*04:02, DQB1*06:01, DQB1*06:09 and DQB1*05:03).
For HLA-DQB1 allelic profile grouping with k-means clustering and PCA, we removed the 12 h time point due to its high number of missing values (caused by insufficient numbers of cells obtained for some individuals), and further excluded another two individuals with missing values, resulting in a total of 44 allelic profiles (2 × 22 individuals). For both of these analyses we used log 2 (FPKM + 1) values. Three clusters captured 64% of the variation in our data, defined by the ratio of between the group sum of squares and the total sum of squares. Two clusters captured a significantly lower amount of between-group variability (37%), and four clusters (70%) had a modest increase from three. PCA was performed on allelic expression profiles with prcomp with center = TRUE, and independently showed that the three clusters identified with k-means separate well (Extended Data Fig. 7) .
HLA-DQ protein-level validations on memory CD4 + T cells.
Ten additional individuals were recruited through the GaP Registry (see 'Study design'). Five individuals were homozygous for Late-Spike alleles: one for DQB1*05:03 and four for DQB1*05:01. Five individuals were homozygous for alleles in the other two cis-regulatory programs (Constant-Low and Fluctuating): one for DQB1*03:02, one for DQB1*02:01, one for DQB1*02:02 and two for DQB1*03:01. Memory CD4 + T cells were isolated and stimulated as explained above. T cells were assayed for expression of HLA-DQ by flow cytometry on day 0 (unstimulated) and days 1, 3 and 7. Additional details for protein quantifications in T cells and B cells are in the Supplementary Note.
Regulatory variant fine mapping. To look for genetic variants in LD with the
Late-Spike haplotype, we called single nucleotide variants (SNVs), small insertions and deletions (INDELs) and classical HLA variants using whole-genome sequences of 2,244 healthy volunteers recruited from the Estonian Genome Project 27 sequenced at 25× coverage. We performed high-resolution (G-group) HLA calling of three class I HLA genes (HLA-A, HLA-B and HLA-C) and three class II HLA genes (HLA-DRB1, HLA-DQA1 and HLA-DQB1) using the HLA*PRG algorithm 66 . We called SNVs and INDELs using GATK v.3.6 according to best practices for variant discovery 67 . In total, we called 246,505 variants in the extended MHC region (29-34 megabase pairs (Mb) on chromosome 6, NCBI Build 37).
To check if any SNVs were in high LD with the Late-Spike haplotype, we first used the Estonian reference panel and restricted our analyses to individuals who carried the alleles present in our 24 individuals (N = 2,198). So, there were 58 individuals with two HLA-DQB1 alleles (at four-digit resolution) pertaining to the Late-Spike haplotype (that is, DQB1*05:01, 05:02, 05:03 or 06:01), 616 with one Late-Spike haplotype allele and 1,524 individuals with zero Late-Spike haplotype alleles. To filter out possible false-positive variants, we next restricted the analyses to SNPs with MAF ≥ 0.05 and within 1 Mb region of the HLA-DQB1 gene (N = 27,210). Next, we computed the r 2 between Late-Spike haplotype dosage (0, 1 or 2) and individual SNP genotypes. Ref-seq gene annotations were used to determine the start and end of HLA-DQB1, HLA-DRB1 and HLA-DQA1.
ATAC-seq experiments and data processing. Memory CD4 + T cells from one new PBMC donor from the GaP Registry were purified and cultured as described above for 72 h with anti-CD3/CD28 stimulation beads. Open chromatin was assessed with ATAC-seq 68, 69 as detailed in the Supplementary Note.
Cell lines. HH cutaneous T cell lines (American Type Culture Collection (ATCC): CRL-2105), Jurkat E6-1 (ATCC: TIB-152) and Daudi (ATCC: CCL-213, provided by M.B.) were cultured in complete RPMI as previously described. The HH cell line was chosen for CRISPR-Cas9 experiments because it is a T cell line that expresses HLA class II and has a transcriptome similar to the 72-h time point in our dataset, when the largest effect of the Late-Spike haplotype occurs ( Supplementary Fig. 13 ).
Bulk CRISPR-Cas9 editing. To investigate regulatory regions around HLA-DQ, the nearest single guide RNA to the SNP of interest was selected using Deskgen online tools (www.deskgen.com). Distances of designed sgRNA to the nearest SNP are shown in Extended Data Fig. 9 . To confirm the sequence of the region, genomic DNA around HLA-DQB1 was amplified by PCR and Sanger sequenced. CRISPR-Cas9 ribonucleoprotein (RNP) complexes were assembled as previously described 70 . Briefly, 40 µM Cas9 protein (QB3 Mircolabs) was mixed with equal volumes of 40 µM modified sgRNA (Synthego) and incubated at 37 °C for 15 min to form RNP complexes. HH cells were nucleofected with 2 µl of RNPs in an Amaxa 4D nucleofector (SE protocol: CL-120). Cells were immediately transferred to 24-well plates with prewarmed media, and cultured. After 7-10 d, HLA-DQ expression was assessed by flow cytometry. Editing was confirmed amplifying genomic DNA by PCR round HLA-DQB1 and sequences were analyzed by tracking of indels by decompostion analysis (tide.deskgen.com). All primer and sgRNA sequences are in Supplementary Table 3 .
CRISPR-Cas9 base editing of rs71542466 in HH cells.
For generation of baseedited cell lines, HH cells were nucleofected with RNPs using sgRNA targeting near rs71542466 and asymmetrical single-stranded DNA donors as previously described 71 . Modified cells were grown for 7-10 d then single-cell sorted using a BD Aria II into 96-well U-bottom plates. After 2-3 months of outgrowth, DNA from surviving clones (194/1,200) was isolated using DNA quick extract solution (Lucigen) following a modified protocol. Briefly, 100 µl of cell culture was spun down, washed once with PBS and then resuspended in 20 µl of DNA extraction solution. Solution was heated in a thermocycler to 65 °C for 15 min, 68 °C for 15 min, 98 °C for 10 min and stored at 4 °C. After DNA extraction, solution was diluted 1:20 and 5 µl was used in a standard 50-µl PCR reaction using Q5 enzyme (NEB). PCR products were Sanger sequenced and analyzed using SnapGene to identify SNP-corrected clones (7/192) , wild-type HH clones (7/192 ) and a single (1/194) insertion/deletion clone. Sequences are shown in Extended Data Fig. 10 . All sgRNA and HDR donor sequences are given in Supplementary Table 3 .
Real-time PCR and flow cytometry analysis of HH clones. For analysis of
HLA-DQB1 expression on HH WT (C/C) and ALT (G/G) clones, RNA was extracted from clones using a Monarch Total RNA extraction kit (NEB). cDNA was synthesized using MaximaH RT (NEB) enzyme following the manufacturer's protocol and oligoDT primers. cDNA was diluted 1 in 4 with HLA-DQB1 (Assay ID: Hs00409790) and actinB (Assay ID: Hs01060665) probes and TaqMan MasterMix (ThermoFisher). Samples were run on an ARIAmx quantitative PCR (qPCR) machine (Agilent) and data analyzed with Aria 1.5 (Agilent) software. Expression is represented as 2 −Δ(HLA-DQB1 Ct − ActinB Ct) . For analysis of protein expression, clones that survived after 3-4 months of culture were washed with PBS and stained with fluorescein isothiocyanate (FITC) anti-HLA-DQ (Biolegend, clone: HLADQ1) for 30 min on ice, and cell-surface expression was assessed by flow cytometry. Data were analyzed using FlowJo and GraphPad Prism.
EMSAs. EMSAs were performed using the LightShift Chemiluminescent EMSA Kit (ThermoFisher Scientific) and single-stranded biotinylated oligonucleotides and complementary sequences corresponding to 31 nucleotides (15 nucleotides flanking the SNP of interest). Nuclear extract from Jurkat, HH and Daudi cells was isolated using the NE-PER nuclear and cytoplasmic extraction kit (ThermoFisher Scientific) with slight modifications. Binding reactions were incubated at room temperature for 30 min and loaded onto a 6% polyacrylamide 0.5× Criterion precast TBE gel (BioRad). After sample electrophoresis and transfer to a nylon membrane, DNA was cross-linked for 10 min, and biotinylated probes were detected by chemiluminescence followed by film exposure. Details can be found in the Supplementary Note, supplementary figures, supplementary tables and source data files.
Luciferase assay.
A double-stranded oligonucleotide containing the SNP of interest (31 nucloetides + restriction enzyme sites) was ordered and annealed as described above. See Supplementary Note for details of the vector preparation. Jurkat, HH and Daudi cells (3 × 10 5 ) were nucleofected with 0.9 µg of pGL3-Promoter vector, along with 0.1 µg of pRL-TK Renilla luciferase vector (Promega) in 16-well strips in a 4D nucleofector with the following protocols and buffers in 20 µl of total volume: Jurkat, SE buffer, CL-120 protocol; HH, SE buffer, CL-120 protocol; Daudi SF buffer, CA-137 protocol. After nucleofection, 180 µl of complete RPMI was added and cells cultured in 96-well, flat-bottom plates (Falcon). After 48 h, cells were spun down, resuspended in 75 µl of fresh complete media and luciferase/Renilla activity measured using the Dual-Glo Luciferase Assay System (Promega). Firefly luciferase activity was expressed as relative luciferase units after correction for Renilla luciferase activity. Data were normalized to those cells transfected with empty pGL3-Promoter vector. Each dot represents an independent nucleofection reaction.
Autoimmune disease enrichment analyses. We downloaded SNPs from the GWAS Catalog on 17 July 2018. We selected SNPs with P < 5 × 10 −8 for 11 autoimmune diseases and 3 nonimmune-mediated diseases, which served as a negative control (schizophrenia, type 2 diabetes, coronary heart disease). We used SNPsea to capture genes within disease loci on the basis of LD and recombination interval information 72 . We then assessed how many of the dynASE genes overlap genes in disease loci for each disease (observed overlap). To assess whether this overlap represented a significant enrichment, for each disease we created 1,000 null sets of N random regions in the genome (N, number of disease loci), which were matched by the number of genes per locus (within 15% of each disease locus). We then calculated the ratio of observed overlap with the mean overlap of our 1,000 null sets (fold enrichment). We calculated the P value as: (number of null overlaps larger than observed overlap + 1)/1,001 (ref. 73 ). We took the same approach for genes with significant ASE at 0 h (N = 501), and eQTL genes of naïve T cells reported by the Blueprint Consortium (N = 5,688) 9 .
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